Anti-Estrogen Receptor ß2 Clone 57/3

Estrogen receptors are commonly over-expressed in cancers. Clone 57/3 recognizes Estrogen Receptor Beta (ERβ) 2 and is useful in determining the expression of ERβ2 in cancer cells via various analysis methods.

Catalogue No. Target Research Areas Applications Size Price (£)
57/3-100UG Estrogen Receptor ß2 Endocrinology
0.1mg 347.00

Form in stock: IgG, purified – 1.0 mg/mL. Also available as unpurified supernatant.
Host: Mouse
Specificity: Recognizes ERβ2 isomer at sequence CGMKMETLLPEATMEQ.
Human Histology positive control: Ovary
Fusion partner: Spleen cells from immunised Balb/c mice were fused with cells of the mouse SP2/0 myeloma cell line.
Storage: Store at +4°C or -20°C. Avoid repeated freezing and thawing.
Shelf life: 18 months from date of dispatch.
Regulatory/ Restrictions: For research and commercial purposes.

Application Suggested Dilution
Western Blot 1:5003,4,8
Immunohistochemistry 1:50-1:500
Immunofluorescence 1:1005
  1. Collins, F., MacPherson, S., Brown, P., Bombail, V., Williams, A. R., Anderson, R. A., … Saunders, P. T. (2009). Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERα. BMC Cancer, 9, 330.
  2. Ciucci, A., Meco, D., De Stefano, I., Travaglia, D., Zannoni, G. F., Scambia, G., … Gallo, D. (2014). Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role? PLoS ONE, 9(7), e101623..
  3. Wong, N. A., Malcomson, R. D., Jodrell, D. I., Groome, N. P., Harrison, D. J. and Saunders, P. T. (2005), ERβ isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J. Pathol., 207: 53–60.
  4. Carpino, Amalia, Vittoria Rago, Vincenzo Pezzi, and Cesare Carani. “Detection of Aromatase and Estrogen Receptors (ERalpha, ERbeta1, ERbeta2) in Human Leydig Cell Tumor.” European Journal of Endocrinology. EJE, 01 Aug. 2007.
  5. Marianna Buttarelli, Floriana Mascilini, Gian Franco Zannoni, Alessandra Ciucci, Enrica Martinelli, Flavia Filippetti, Giovanni Scambia, Gabriella Ferrandina, Daniela Gallo, Hormone receptor expression profile of low-grade serous ovarian cancers, Gynecologic Oncology, Volume 145, Issue 2, May 2017, Pages 352-360, ISSN 0090-8258.
  6. Rago, V., Romeo, F., Giordano, F., Ferraro, A., Andò, S., & Carpino, A. (2009). Identification of ERβ1 and ERβ2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia. Reproductive Biology and Endocrinology : RB&E, 7, 56. IHC-P, Dilution used 1:100.
  7. Skliris, G. P., Leygue, E., Curtis-Snell, L., Watson, P. H., & Murphy, L. C. (2006). Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours. British Journal of Cancer, 95(5), 616–626. IHC-P, Dilution used 1:20.
  8. Ogawa, S., Inoue, S., Watanabe, T., Orimo, A., Hosoi, T., Ouchi, Y., & Muramatsu, M. (1998). Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Research, 26(15), 3505–3512. WB, Dilution used 1:500.
  9. Hilary O. D. Critchley, Teresa A. Henderson, Rodney W. Kelly, Graeme S. Scobie, Lee R. Evans, Nigel P. Groome, Philippa T. K. Saunders; Wild-Type Estrogen Receptor (ERβ1) and the Splice Variant (ERβcx/β2) Are Both Expressed within the Human Endometrium throughout the Normal Menstrual Cycle. J Clin Endocrinol Metab 2002; 87 (11): 5265-5273. IHC-P, Dilution used 1:50.
  10. Zannoni G F, Ciucci A, Marucci G, Travaglia D, Stigliano E, Foschini M P, Scambia G & Gallo D (2016) Histopathology68, 541–548. IHC-P, Dilution used 1:10.

Clone 57/3 used to detect expression of ERβ2 in cancer tissue by IHC-P

Image caption: Immunoexpression of ERs in endometrial cancers. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; …immunoexpression of ERβ1, 2, 5 was readily detected (K. L, M). Inserts in panels K, L, and M show negative controls for ERβ1, ERβ2 and ERβ5 antibodies respectively generated using primary antibodies pre-absorbed with specific peptides used for immunisation. Asterisks (*) label the stromal compartment that was well defined in the well differentiated cancers. (Collins, F et al.)
Dilution used: 1:30

Clone 57/3 used to detect ERβ2 expression in normal human liver by IHC-P

Image caption: Staining pattern of the ERß isoforms in human liver. In order to confirm the specificity of the ERß antibodies used in the study, we immunostained sections of human healthy liver, showing that ERß1 and ERß2 isoforms are not expressed, while specific nuclear ERß5 immunoreactivity is detected (magnification 20x and 40x). This pattern of ERß isoforms immunoreactivity is consistent with previous descriptions. (Ciucci, A et al.)
Dilution used: 1:100

Clone 57/3 used to detect expression of ERβ2 in Leydig cell tumors by IHC-P

Image caption: Morphology and immunolocalization of aromatase and estrogen receptors in Leydig cell tumors (A and B) and control testis (C). A–C: Hematoxylin–eosin staining. A1–C1: Aromatase immunolocalization. A2–C2: ERα immunoreactivity. A3–C3: ERβ1 immunodetection. A4–C4: ERβ2 immunolocalization. L, Leydig cells; T, seminiferous tubule. (Carpino, A et al.)
Dilution used: 1:100

Clone 57/3 used to detect expression of ERβ2 in colorectal tissue by Western Blot

Image caption: (A) ERβ1, 2 and 5 mRNA expression (assessed by RT-PCR) and (B) ERβ1 and 2 protein expression (assessed by western blotting) by 10 colorectal carcinoma cell lines… (Wong, N. A et al.)
Dilution used: 1:500

Clone 57/3 used to detect expression of ERβ2 in ovarian cancer cells by Immunofluorescence

Image caption: A) Representative pictures for ERα, ERβ1, ERβ2, ERβ5, PR, and AR immunostaining in LGSOC patients (magnification 20 ×) and bar chart showing levels of hormone receptor expression (mean ± SEM, n = 25). Results are expressed as IRS (Immunoreactive receptor score). B) Representative pictures showing exclusive nuclear and nuclear/cytoplasmic ERβ2 expression in primary tumor and matched peritoneal metastasis.(Buttarelli, M et al.)
Dilution used: 1:100